Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6266170 | 0.87 | MTTP (0.66) | MTTPGAACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15556509 | 0.87 | MTTP (0.66) | MTTPGAACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6805732 | 0.84 | MTTP (1.00) | MTTP | |
| SCHEMBL6805734 | 0.84 | MTTP (1.00) | MTTP | |
| SCHEMBL15606189 | 0.84 | MTTP (0.61) | MTTPGAACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7037178 | 0.82 | MTTP (0.53) | MTTPEPHX2NR1H4PPARG | |
| SCHEMBL3726223 | 0.81 | NPC1 (0.61) | MTTPCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7609454 | 0.81 | PPARG (0.59) | MTTPPPARG | |
| SCHEMBL6788420 | 0.80 | MTTP (0.57) | MTTPGAAKDM1AHDAC1 | |
| SCHEMBL7607440 | 0.80 | MTTP (0.57) | MTTPGAAPPARGKDM1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578725-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | MTTP 1/4885GAA 523/4885CHRNB2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.